You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

List of Excipients in API LENALIDOMIDE


✉ Email this page to a colleague

« Back to Dashboard


Excipients in NDA-approved (novel) drugs containing LENALIDOMIDE

Glossary
Company Tradename Ingredient NDC Excipient Potential Generic Entry
Celgene Corporation REVLIMID lenalidomide 59572-402 ANHYDROUS LACTOSE
Celgene Corporation REVLIMID lenalidomide 59572-402 CELLULOSE, MICROCRYSTALLINE
Celgene Corporation REVLIMID lenalidomide 59572-402 CROSCARMELLOSE SODIUM
Celgene Corporation REVLIMID lenalidomide 59572-402 MAGNESIUM STEARATE
>Company >Tradename >Ingredient >NDC >Excipient >Potential Generic Entry

Subscribe to access the full database, or Sign Up

Excipients in ANDA-approved (generic) drugs containing LENALIDOMIDE

Company Ingredient NDC Excipient
Mylan Pharmaceuticals Inc lenalidomide 0378-1935 AMMONIA
Mylan Pharmaceuticals Inc lenalidomide 0378-1935 CELLULOSE, MICROCRYSTALLINE
Mylan Pharmaceuticals Inc lenalidomide 0378-1935 CROSCARMELLOSE SODIUM
Mylan Pharmaceuticals Inc lenalidomide 0378-1935 FD&C BLUE NO. 2
Mylan Pharmaceuticals Inc lenalidomide 0378-1935 FERRIC OXIDE YELLOW
Mylan Pharmaceuticals Inc lenalidomide 0378-1935 FERROSOFERRIC OXIDE
Mylan Pharmaceuticals Inc lenalidomide 0378-1935 GELATIN
>Company >Ingredient >NDC >Excipient

Subscribe to access the full database, or Sign Up

Detailed excipient profiles for LENALIDOMIDE

Excipient focus: AMMONIA

Excipient focus: ANHYDROUS LACTOSE

Excipient focus: CELLULOSE, MICROCRYSTALLINE

Excipient focus: CROSCARMELLOSE SODIUM

Excipient focus: FD&C BLUE NO. 1

Excipient focus: FD&C BLUE NO. 2

Excipient focus: FD&C RED NO. 3

Excipient focus: FD&C RED NO. 40

Excipient focus: FD&C YELLOW NO. 6

Excipient focus: FERRIC OXIDE RED

Excipient focus: FERRIC OXIDE YELLOW

Excipient focus: FERROSOFERRIC OXIDE

Excipient focus: GELATIN

Excipient focus: LACTOSE MONOHYDRATE

Excipient focus: MAGNESIUM STEARATE

Excipient focus: MANNITOL

Excipient focus: MICROCRYSTALLINE CELLULOSE 102

LENALIDOMIDE drug variants not containing MICROCRYSTALLINE CELLULOSE 102

Company Ingredient NDC
Mylan Pharmaceuticals Inc lenalidomide 0378-1935
Mylan Pharmaceuticals Inc lenalidomide 0378-1936
Teva Pharmaceuticals Inc lenalidomide 0480-1241
Teva Pharmaceuticals Inc lenalidomide 0480-1242
Camber Pharmaceuticals Inc lenalidomide 31722-257
Dr Reddy's Laboratories Inc lenalidomide 43598-516
Alvogen Inc lenalidomide 47781-483
>Company >Ingredient >NDC

Subscribe to access the full database, or Sign Up

Excipient focus: POTASSIUM HYDROXIDE

LENALIDOMIDE drug variants containing POTASSIUM HYDROXIDE

Company Ingredient NDC
Mylan Pharmaceuticals Inc lenalidomide 0378-1935
Mylan Pharmaceuticals Inc lenalidomide 0378-1936
Teva Pharmaceuticals Inc lenalidomide 0480-1241
Teva Pharmaceuticals Inc lenalidomide 0480-1242
Camber Pharmaceuticals Inc lenalidomide 31722-257
Dr Reddy's Laboratories Inc lenalidomide 43598-516
Aurobindo Pharma Limited lenalidomide 59651-342
>Company >Ingredient >NDC

Subscribe to access the full database, or Sign Up

Excipient focus: POVIDONE

Excipient focus: PROPYLENE GLYCOL

Excipient focus: SHELLAC

Excipient focus: SILICON DIOXIDE

Excipient focus: SODIUM STEARYL FUMARATE

Excipient focus: STARCH, CORN

Excipient focus: TITANIUM DIOXIDE

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2024 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
 NCE-1 Patent Challenge Dates 2024 - 2025
 Trigger-based marketing for the life sciences
 Get DrugPatentWatch Business Intelligence Reports at Amazon.com
 DrugChatter - AI-based answers to questions about drugs
 RxJam - Digital Marketing for Life Sciences
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links

Follow DrugPatentWatch:

  DrugPatentWatch Linkedin Group